Los buenos resultados obtenidos en los ensayos clínicos de fase II de un fármaco para la amiloidosis han motivado el lanzamiento de la iniciativa
Read moreBy activating the PPAR receptors, ABTL0812 induces over-expression of TRIB3 protein, which binds to the Akt oncogene and inhibits the Akt/mTOR axis.
Read moreAlbaJuna Therapeutics is developing a new treatment strategy based on monoclonal antibodies with great potential to neutralize HIV and activate the “natural killer” cells responsible for destroyin...
Read moreLa Micro-Inmunoterapia es el mejor aliado del sistema inmunitario, ya que utiliza su mismo lenguaje para tratar diferentes enfermedades. Gracias al laboratorio farmacéutico Labo’ Life se crean medi...
Read moreEl laboratorio farmacéutico Labo’Life, pyme situada en la isla de Mallorca, destaca por su constancia en la inversión en I+D ejercida durante los últimos años. Su objetivo es la mejora continua ...
Read moreResearchers from UAB describe for the first time, in a work published in PLOS ONE, a model of behaviour of a bacterial colony that shows how the colony protects itself against toxic substances, like a...
Read moreEpigenetic approaches to modify the progression of various neurodegenerative diseases focus on producing changes in patterns of gene expression in neurons and also in glia cells and are of interest fo...
Read moreEl principal objetivo de LBLONCOVIRUS es desarrollar un nuevo sistema de nanopartículas adenovirales recubiertas artificialmente con un sistema funcionalizado polimérico multicapa, para el tratamien...
Read moreThe results of the investigation directly benefit hundred patients’ participants in the clinical project, and should be the key to the implementation of the best therapy for each patient to lengthen...
Read moreThe potential drugs show high efficacy and low toxicity
Read moreThis discovery not only advances understanding of the mechamisms underlying this disease; it could also support the development of new strategies to treat or even prevent the disease.
Read moreThe molecules synthesized by Ernest Giralt’s lab at IRB Barcelona bind a key protein in cancer that has received little attention as a therapeutic target. The long-term goal is to provide a new chem...
Read more